<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505190</url>
  </required_header>
  <id_info>
    <org_study_id>YP39432</org_study_id>
    <nct_id>NCT03505190</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RO7062931 in Healthy Chinese Volunteers.</brief_title>
  <official_title>A Randomized, Sponsor-Open, Investigator-Blind, Subject-Blind, Placebo-Controlled, Single Ascending Dose, to Investigate the Safety, Tolerability and Pharmacokinetics of RO7062931 Following Subcutaneously Administration in Healthy Chinese Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized study will evaluate the safety, tolerability and pharmacokinetics of single
      ascending subcutaneously administered doses of RO7062931 in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2018</start_date>
  <completion_date type="Anticipated">November 6, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 6, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with Adverse Events and AEs of Special Interest</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation and Urinalysis Test Results</measure>
    <time_frame>Baseline, Day 2, 8, 15, 29, 85</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>Baseline; pre-dose, 1 hour (h), 4, 8, 12h post-dose Day 1, 24h post-dose Day 2, 8, 15, 29, 85</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Abnormalities in Vital Signs, Including Blood Pressure, Pulse Rate and Temperature</measure>
    <time_frame>Baseline; pre-dose, 1, 4, 8, 12h post-dose Day 1, 24h post-dose Day 2, 3, 4, 5, 6, 8, 15, 29, 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) for RO7062931</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) for RO7062931</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUC0-inf) for RO7062931</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time Zero until the Last Quantifiable Time-Point (AUC0-last) for RO7062931</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Rate Constant (k) for RO7062931</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2) for RO7062931</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) for RO7062931</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) for RO7062931</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18h post-dose Day 1, 24, 30, 36h post-dose Day 2, Day 3, 4, 5, 6, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Amount of RO7062931 Excreted in Urine (Ae)</measure>
    <time_frame>(0-4), (4-8), (8-12), (12-24)h post-dose Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight participants will be administered subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931 and two participants will receive matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight participants will be administered subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931 and two participants will receive matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight participants will be administered subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931 and two participants will receive matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight participants will be administered subcutaneously (SC) 3.0 milligram per kilogram (mg/kg) of RO7062931 and two participants will receive matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 (Optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight participants will be administered subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931 and two participants will receive matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7062931</intervention_name>
    <description>RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5 (Optional)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo will be administered subcutaneously (SC).</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5 (Optional)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chinese healthy male and female (of non-childbearing potential) volunteers.

          -  A Body Mass Index (BMI) between 19 to 27 kilogram per square meter (kg/m2) inclusive
             and a body weight of at least 45 kg.

          -  Women should be of non-childbearing potential. These include those who have undergone
             surgical sterilization (removal of ovaries and/or uterus) or are post-menopausal.

          -  Men must agree to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive measures during treatment and up to 105 days after the last dose of
             RO7062931, and agree to refrain from donating sperm during this same period.

          -  Non-smoker (nor tobacco containing products) for at least 90 days prior to dosing on
             Day 1 and agree to remain as non-smoker during the study.

        Exclusion Criteria:

          -  History of drug or alcohol abuse or dependence in previous 6 months.

          -  Positive urine drug and alcohol screen or positive cotinine test at Screening or Day
             -1.

          -  Positive result on hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency
             virus (HIV)-1 and -2 at Screening.

          -  Confirmed blood pressure or resting pulse rate outside of accepted ranges.

          -  Participation in an investigational drug or device study within 90 days prior to
             screening.

          -  Donation of blood over 500 milliliters (mL) within three months prior to screening.

          -  Any major illness within the one month, or any febrile illness within two weeks
             preceding the screening visit.

          -  Alcohol consumption of more than 2 standard drinks per day on average.

          -  Screening or baseline ECG evidence of atrial fibrillation, atrial flutter, complete
             right or left bundle branch block, Wolff-Parkinson-White syndrome, or cardiac
             pacemaker.

          -  Any out of range findings in liver function tests, INR and renal function tests or any
             clinically significant abnormalities (as judged by the Investigator) in the physical
             examination and in the remaining laboratory test results (including hepatic and renal
             panels, complete blood count, chemistry panel and urinalysis) at Screening or on
             Day-1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>reference Study ID Number: YP39432 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>April 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

